Could Gene-Replacement Therapy End Alzheimer’s? by Dr. Bruce Lasker

Recent findings by Icelandic gene researchers indicate that such a solution may be the answer. A genetic study of nearly 2,000 participants found the presence of a particular gene mutation was strongly linked to the absence of Alzheimer’s, as well as with significantly better cognitive function between the ages of 80 and 100 when compared with peers.

The gene that may control Alzheimer’s is referred to as APP, or amyloid precursor protein, and creates amyloid-beta, which is the “plaque” that inhibits proper neuron function. Those with the mutation show a 40-percent reduction in amyloid-beta production, while a different APP mutation is linked to early-onset Alzheimer’s. Studying the variety of APP mutations may reveal a spectrum of vulnerability to the disease.

While gene-replacement therapy is relatively new and still only in early testing stages, significant results are emerging to spur future research. Successful trials for inherited blindness disorders and several types of genetically linked cancers have yielded full success. With the discovery of an Alzheimer’s resistant gene, we may see an end to the disease in the next 50 years.

Dr. Bruce Lasker, neurologist, is a graduate of Northwestern University Feinberg School of Medicine and specializes in geriatric neurology with Pacific Neurology in San Diego.